Study to Evaluate the Effect of Simvastatin, Losartan and Pioglitazone on Patients With Peripheral Arterial Disease. (LEAP)
Two-Part,Multicenter,Randomized,Double-Blind,Placebo-Controlled,Study to Evaluate the Effect of Simvastatin,Losartan,and Pioglitazone on Cardiovascular Disease Biomarkers in Lower Extremity Atherosclerotic Plaque Excised From Patients w/PAD
Sponsor: FoxHollow Technologies
A EARLY_PHASE1 clinical study on Peripheral Arterial Disease, this trial is completed. The trial is conducted by FoxHollow Technologies and has accumulated 8 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed EARLY_PHASE1
-
Jun 2022 — Jul 2024 [monthly]
Completed EARLY_PHASE1
-
Jun 2021 — Jun 2022 [monthly]
Completed EARLY_PHASE1
-
Jan 2021 — Jun 2021 [monthly]
Completed EARLY_PHASE1
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed EARLY_PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed EARLY_PHASE1
Phase: Phase 0 → EARLY_PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed Phase 0
First recorded
Dec 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- FoxHollow Technologies
- Medtronic Endovascular
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.